Regular serum screening

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Regular serum screening is one of 6 biologic programs targeting Screening. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScreeningCompleted

ScreeningPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Screening

#DrugCompanyPhaseTrials

Acetylsalicylic Acid

Bayer

Phase 2

1 2

Ulipristal Acetate

AbbVie

Phase 2

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

—4

Epsom Salt

FFresenius Kabi USA, LLC

Phase 1

—5

Cytisine

AAchieve Life Sciences

Phase 2

1 6

Regular serum screening

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Screening1 trial

T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02424474·933 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regular serum screening. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Regular serum screening compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Regular serum screening. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Regular serum screening

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Screening1 trial

References

Drug Info

Quick Facts

Related News